Akihiro Kobayashi
Interventional Cardiology · Mountain Home, ARNPI 1700226768
Payments from drug & device makers
What this record shows
This record is dominated by grants: $13,000 of the $17,425 with a category attached, or 74.6%. Medtronic accounts for 80.0% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $13,520 and has fallen 95.1% since, to $667 in 2025.
Across 139 payments — averaging $125.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$14K
- Edwards Lifesciences$2K
- Abbott$322
- Pfizer$227
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$156
- Boston Scientific$116
- plus $891 from 23 others
What the payments were for
- Grants$13,00075%
- Travel & lodging$1,0266%
- Food & beverage$3,39920%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 39 | $13,936 |
| Edwards Lifesciences | 16 | $1,777 |
| Abbott | 11 | $322 |
| Pfizer | 13 | $227 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $156 |
| Boston Scientific | 4 | $116 |
| Cardiva Medical, Inc. | 3 | $109 |
| Merck | 6 | $102 |
| Amgen | 6 | $91 |
| Novartis | 5 | $83 |
| AstraZeneca(2 entities) | 5 | $71 |
| Abiomed | 1 | $55 |
| Lundbeck LLC | 2 | $33 |
| Heartflow, Inc. | 2 | $32 |
| Terumo Medical Corporation | 1 | $27 |
| Cvrx, Inc. | 1 | $25 |
| Philips North America LLC | 1 | $24 |
| Irhythm Technologies, Inc. | 1 | $24 |
| Sanofi | 1 | $23 |
| Baxter Healthcare | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Novo Nordisk | 1 | $22 |
| Getinge USA Sales, LLC | 1 | $21 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Bayer | 1 | $19 |
| Lantheus Medical Imaging, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,425 in reported general payments places this provider in the 80th percentile of 89 interventional cardiology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 195 | $159,477 |
| EntrestoSacubitril/Valsartan | 77 | $73,961 |
| XareltoRivaroxaban | 62 | $53,501 |
| BrilintaTicagrelor | 36 | $21,988 |
| Repatha SureclickEvolocumab | 11 | $5,761 |
| Rosuvastatin Calcium | 528 | $3,964 |
| Atorvastatin Calcium | 422 | $2,798 |
| Losartan Potassium | 232 | $1,914 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 279 | $1,853 |
| ClopidogrelClopidogrel Bisulfate | 136 | $1,343 |
| Metoprolol Succinate | 110 | $1,173 |
| Nitroglycerin | 118 | $1,018 |
| Metoprolol Tartrate | 293 | $909 |
| Ranolazine ErRanolazine | 14 | $849 |
| Prasugrel Hcl | 16 | $814 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $227 | $159,477195 claims |
| NovartisEntresto | $83 | $73,96177 claims |
| Johnson & JohnsonXarelto | $15 | $53,50162 claims |
| AstraZenecaBrilinta | $71 | $21,98836 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 89 interventional cardiology providers in Arkansas.
Other interventional cardiology in Mountain Home
- Timothy BowenMountain Home$8K
- Michael CampMountain Home$7K
- Gaurav DharLittle Rock$206K
- Ernesto Ruiz-RodriguezLittle Rock$153K
- Vasili LendelLittle Rock$86K
- Thomas WattsLittle Rock$68K
- Vijay RajaLittle Rock$46K
- Lena AwarJonesboro$43K
- Zubair AhmedFayetteville$36K
- Stephen BroughtonLittle Rock$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.